Publications
262 results found
Loebinger MR, Birring SS, 2020, Patient reported outcomes for non-tuberculous mycobacterial disease, EUROPEAN RESPIRATORY JOURNAL, Vol: 55, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 4
Chalmers JD, van der Laan R, Crichton M, et al., 2020, Non-Tuberculous Mycobacteria Testing in Bronchiectasis Patients in Europe: Data from the Embarc Registry, International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
Loebinger M, Polverino E, Blasi F, et al., 2020, Efficacy and Safety of Different Doses of Tobramycin Inhalation Powder in Patients with Bronchiectasis and Pulmonary Pseudomonas Aeruginosa Infection: Results from the iBest-1 Study, International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 1
Rubbo B, Shoemark A, Legendre M, et al., 2020, Topological Data Analysis Coupled with Machine Learning Reveals New Genotype-Phenotype Relationships in Primary Ciliary Dyskinesia, International Conference of the American-Thoracic-Society (ATS), Publisher: AMER THORACIC SOC, ISSN: 1073-449X
Walsh JA, Patel S, Barker RE, et al., 2020, The minimum clinically important difference of the incremental shuttle walk test in bronchiectasis: a prospective cohort study., Annals of the American Thoracic Society, Vol: 17, ISSN: 1546-3222
The incremental shuttle walk test (ISW) is an externally-paced field walking test thatmeasures maximal exercise capacity1 and is widely used in patients with chronic obstructivepulmonary disease (COPD) undergoing pulmonary rehabilitation (PR). Its psychometricproperties, including reliability, construct validity2 and responsiveness to intervention,2-5have been demonstrated in patients with bronchiectasis, but little data exist on theminimum clinically important difference (MCID). Although two studies have investigated theMCID of ISW in patients with bronchiectasis, the generalisability of these data is limitedbecause of the study sample characteristics,6 or did not involve an exercise-basedintervention.2 The MCID enables clinicians and researchers to understand the clinicalsignificance of change data and forms an important part of the evidence required byregulatory agencies for approval for use in clinical trials. Accordingly, the aim of this studywas to provide MCID estimates of the ISW in response to intervention, namely PR, inpatients with bronchiectasis.
Bradley JM, Anand R, O'Neill B, et al., 2019, A 2 x 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial, TRIALS, Vol: 20
- Author Web Link
- Cite
- Citations: 5
Stagg HR, Bothamley GH, Davidson JA, et al., 2019, Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance, EUROPEAN RESPIRATORY JOURNAL, Vol: 54, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 13
Halbeisen FS, Shoemark A, Barbato A, et al., 2019, Time trends in diagnostic testing for primary ciliary dyskinesia in Europe, EUROPEAN RESPIRATORY JOURNAL, Vol: 54, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 7
Loebinger MR, Polverino E, Blasi F, et al., 2019, Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with <i>P</i>. <i>aeruginosa</i> infection: Design of a dose-finding study (iBEST-1), PULMONARY PHARMACOLOGY & THERAPEUTICS, Vol: 58, ISSN: 1094-5539
- Author Web Link
- Cite
- Citations: 8
Rademacher J, Dettmer S, Fuge J, et al., 2019, Derivation und Validation of a Primary Ciliary Dyskinesia Computed Tomography (PCD-CT) Score in patients with bronchiectasis, International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Wynne S, Patel S, Barker R, et al., 2019, The effect of pulmonary rehabilitation (PR) on anxiety and depression symptoms in bronchiectasis: a propensity-matched study, International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Ringshausen FC, Chalmers JD, Polverino E, et al., 2019, New isolation of non-tuberculous mycobacteria in patients with bronchiectasis - data from the European Bronchiectasis Registry (EMBARC), International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 2
Aliberti S, Menendez R, Blasi F, et al., 2019, Determinants of survival in the European Bronchiectasis Registry(EMBARC), International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Walsh J, Patel S, Barker RE, et al., 2019, The incremental shuttle walk test (ISW) in patients with bronchiectasis: Response to pulmonary rehabilitation (PR) and minimum clinically important difference (MCID), International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Wynne S, Patel S, Barker RE, et al., 2019, The Hospital Anxiety and Depression Scale (HADS) in Bronchiectasis: Response to pulmonary rehabilitation (PR) and Minimum Clinically Important Difference (MCID), International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Burgel P-R, Polverino E, Harworth C, et al., 2019, Risk factors for new P. aeruginosa isolation in bronchiectasis- data from the European Bronchiectasis Registry (EMBARC), International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Kouis P, Goutaki M, Halbeisen FS, et al., 2019, Prevalence and course of disease after lung resection in primary ciliary dyskinesia: a cohort & nested case-control study, Respiratory Research, Vol: 20, Pages: 1-12, ISSN: 1465-9921
BackgroundLung resection is a controversial and understudied therapeutic modality in Primary Ciliary Dyskinesia (PCD). We assessed the prevalence of lung resection in PCD across countries and compared disease course in lobectomised and non-lobectomised patients.MethodsIn the international iPCD cohort, we identified lobectomised and non-lobectomised age and sex-matched PCD patients and compared their characteristics, lung function and BMI cross-sectionally and longitudinally.ResultsAmong 2896 patients in the iPCD cohort, 163 from 20 centers (15 countries) underwent lung resection (5.6%). Among adult patients, prevalence of lung resection was 8.9%, demonstrating wide variation among countries. Compared to the rest of the iPCD cohort, lobectomised patients were more often females, older at diagnosis, and more often had situs solitus. In about half of the cases (45.6%) lung resection was performed before presentation to specialized PCD centers for diagnostic work-up. Compared to controls (n = 197), lobectomised patients had lower FVC z-scores (− 2.41 vs − 1.35, p = 0.0001) and FEV1 z-scores (− 2.79 vs − 1.99, p = 0.003) at their first post-lung resection assessment. After surgery, lung function continued to decline at a faster rate in lobectomised patients compared to controls (FVC z-score slope: − 0.037/year Vs − 0.009/year, p = 0.047 and FEV1 z-score slope: − 0.052/year Vs − 0.033/year, p = 0.235), although difference did not reach statistical significance for FEV1. Within cases, females and patients with multiple lobe resections had lower lung function.ConclusionsPrevalence of lung resection in PCD varies widely between countries, is often performed before PCD diagnosis and overall is more frequent in patients with delayed diagnosis. After lung resection, compared to controls most lobectomised pa
Cowman S, van Ingen J, Griffith DE, et al., 2019, Non-tuberculous mycobacterial pulmonary disease, EUROPEAN RESPIRATORY JOURNAL, Vol: 54, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 118
Tortoli E, Brown-Elliott BA, Chalmers JD, et al., 2019, Same meat, different gravy: ignore the new names of mycobacteria, EUROPEAN RESPIRATORY JOURNAL, Vol: 54, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 38
Gruffydd-Jones K, Keeley D, Knowles V, et al., 2019, Primary care implications of the British Thoracic Society Guidelines for bronchiectasis in adults 2019, npj Primary Care Respiratory Medicine, Vol: 29, ISSN: 2055-1010
The British Thoracic Society (BTS) Guidelines for Bronchiectasis in adults were published in January 2019, and comprise recommendations for treatment from primary to tertiary care. Here, we outline the practical implications of these guidelines for primary care practitioners. A diagnosis of bronchiectasis should be considered when a patient presents with a recurrent or persistent (>8 weeks) productive cough. A definitive diagnosis is made by using thin-section chest computed tomography (CT). Once diagnosed, patients should be initially assessed by a specialist respiratory team and a shared management plan formulated with the patient, the specialist and primary care teams. The cornerstone of primary care management is physiotherapy to improve airway sputum clearance and maximise exercise capacity, with prompt treatment of acute exacerbations with antibiotics.
Schuetz K, Alecsandru D, Grimbacher B, et al., 2019, Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group (vol 39, pg 45, 2019), JOURNAL OF CLINICAL IMMUNOLOGY, Vol: 39, Pages: 225-227, ISSN: 0271-9142
Lucas JS, Gahleitner F, Amorim A, et al., 2019, Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials, ERJ Open Research, Vol: 5, ISSN: 2312-0541
Pulmonary exacerbations are a cause of significant morbidity in patients with primary ciliary dyskinesia (PCD) and are frequently used as an outcome measure in clinical research into chronic lung diseases. So far, there has been no consensus on the definition of pulmonary exacerbations in PCD. 30 multidisciplinary experts and patients developed a consensus definition for children and adults with PCD. Following a systematic review, the panel used a modified Delphi process with a combination of face-to-face meetings and e-surveys to develop a definition that can be used in research settings for children and adults with PCD. A pulmonary exacerbation was defined by the presence of three or more of the following seven items: 1) increased cough, 2) change in sputum volume and/or colour, 3) increased shortness of breath perceived by the patient or parent, 4) decision to start or change antibiotic treatment because of perceived pulmonary symptoms, 5) malaise, tiredness, fatigue or lethargy, 6) new or increased haemoptysis, and 7) temperature >38°C. The consensus panel proposed that the definition should be used for future clinical trials. The definition should be validated and the usability assessed during these studies.
Best S, Shoemark A, Rubbo B, et al., 2019, Risk factors for situs defects and congenital heart disease in primary ciliary dyskinesia, THORAX, Vol: 74, Pages: 203-205, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 38
Patel S, Cole AD, Nolan CM, et al., 2019, Pulmonary rehabilitation in bronchiectasis: a propensity-matched study, European Respiratory Journal, Vol: 53, ISSN: 0903-1936
International guidelines recommend pulmonary rehabilitation for patients with bronchiectasis, supported by small trials and data extrapolated from chronic obstructive pulmonary disease (COPD). However, it is unknown whether real-life data on completion rates and response to pulmonary rehabilitation are similar between patients with bronchiectasis and COPD.Using propensity score matching, 213 consecutive patients with bronchiectasis referred for a supervised pulmonary rehabilitation programme were matched 1:1 with a control group of 213 patients with COPD. Completion rates, change in incremental shuttle walk (ISW) distance and change in Chronic Respiratory Disease Questionnaire (CRQ) score with pulmonary rehabilitation were compared between groups.Completion rate was the same in both groups (74%). Improvements in ISW distance and most domains of the CRQ with pulmonary rehabilitation were similar between the bronchiectasis and COPD groups (ISW distance: 70 versus 63 m; CRQ-Dyspnoea: 4.8 versus 5.3; CRQ-Emotional Function: 3.5 versus 4.6; CRQ-Mastery: 2.3 versus 2.9; all p>0.20). However, improvements in CRQ-Fatigue with pulmonary rehabilitation were greater in the COPD group (bronchiectasis 2.1 versus COPD 3.3; p=0.02).In a real-life, propensity-matched control study, patients with bronchiectasis show similar completion rates and improvements in exercise and health status outcomes as patients with COPD. This supports the routine clinical provision of pulmonary rehabilitation to patients with bronchiectasis.
Hill AT, Sullivan AL, Chalmers JD, et al., 2019, British Thoracic Society Guideline for bronchiectasis in adults, THORAX, Vol: 74, Pages: 1-54, ISSN: 0040-6376
Schütz K, Alecsandru D, Grimbacher B, et al., 2019, Imaging of bronchial pathology in antibody deficiency: data from the European Chest CT Group, Journal of Clinical Immunology, Vol: 39, Pages: 45-54, ISSN: 0271-9142
Studies of chest computed tomography (CT) in patients with primary antibody deficiency syndromes (ADS) suggest a broad range of bronchial pathology. However, there are as yet no multicentre studies to assess the variety of bronchial pathology in this patient group. One of the underlying reasons is the lack of a consensus methodology, a prerequisite to jointly document chest CT findings. We aimed to establish an international platform for the evaluation of bronchial pathology as assessed by chest CT and to describe the range of bronchial pathologies in patients with antibody deficiency. Ffteen immunodeficiency centres from 9 countries evaluated chest CT scans of patients with ADS using a predefined list of potential findings including an extent score for bronchiectasis. Data of 282 patients with ADS were collected. Patients with common variable immunodeficiency disorders (CVID) comprised the largest subgroup (232 patients, 82.3%). Eighty percent of CVID patients had radiological evidence of bronchial pathology including bronchiectasis in 61%, bronchial wall thickening in 44% and mucus plugging in 29%. Bronchiectasis was detected in 44% of CVID patients aged less than 20 years. Cough was a better predictor for bronchiectasis than spirometry values. Delay of diagnosis as well as duration of disease correlated positively with presence of bronchiectasis. The use of consensus diagnostic criteria and a pre-defined list of bronchial pathologies allows for comparison of chest CT data in multicentre studies. Our data suggest a high prevalence of bronchial pathology in CVID due to late diagnosis or duration of disease.
Hill AT, Welham SA, Sullivan AL, et al., 2019, Updated BTS Adult Bronchiectasis Guideline 2018: a multidisciplinary approach to comprehensive care, THORAX, Vol: 74, Pages: 1-3, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 70
Garner J, Garner S, Hardie R, et al., 2019, Evaluation of a Low Cost, Re-Useable, Bronchoscopy Biosimulator with Ventilated Lungs: The Bronchoscopy BioSim, International Conference of the American-Thoracic-Society, Publisher: AMER THORACIC SOC, ISSN: 1073-449X
Hill AT, Sullivan AL, Chalmers JD, et al., 2018, British Thoracic Society guideline for bronchiectasis in adults, BMJ Open Respiratory Research, Vol: 5, ISSN: 2052-4439
The full British Thoracic Society Guideline for Bronchiectasis in Adults is published in Thorax. The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline. The appendices are available in the full guideline.
Cowman SA, James P, Wilson R, et al., 2018, Profiling mycobacterial communities in pulmonary nontuberculous mycobacterial disease, PLoS ONE, Vol: 13, ISSN: 1932-6203
The diagnosis of pulmonary non-tuberculous mycobacterial disease (pNTM) is dependent on the isolation of NTM in culture, which is prone to overgrowth and contamination and may not capture the diversity of mycobacteria present, including rare or unidentified species. This study aimed to develop a culture independent method of detecting and identifying mycobacteria from sputum samples using partial sequencing of the hsp65 gene. DNA was extracted from sputum samples from subjects with pNTM and disease controls. Multiplexed partial sequencing of the hsp65 gene was performed using the Illumina MiSeq and custom primers. A reference database of hsp65 sequences was created for taxonomy assignment. Sequencing results were obtained from 42 subjects (31 cases, 11 controls). Mycobacterial sequences were identified in all subjects. In 90.5% of samples more than one species was found (median 5.5). The species isolated in culture was detected by sequencing in 81% of subjects and was the most abundant species in 62%. The sequencing of NTM from clinical samples reveals a far greater diversity than conventional culture and suggests NTM are present as communities rather than a single species. NTM were found to be present even in the absence of isolation in culture or clinical disease.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.